Virtu Financial LLC Invests $186,000 in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Virtu Financial LLC bought a new stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 107,544 shares of the company’s stock, valued at approximately $186,000.

A number of other large investors also recently added to or reduced their stakes in TSHA. Cibc World Markets Corp purchased a new position in Taysha Gene Therapies in the 4th quarter worth approximately $28,000. E Fund Management Co. Ltd. purchased a new position in shares of Taysha Gene Therapies in the fourth quarter worth $31,000. Intech Investment Management LLC bought a new stake in Taysha Gene Therapies during the 3rd quarter valued at $85,000. Commonwealth Equity Services LLC boosted its position in Taysha Gene Therapies by 110.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 59,069 shares of the company’s stock valued at $102,000 after buying an additional 31,000 shares during the period. Finally, MetLife Investment Management LLC grew its holdings in Taysha Gene Therapies by 81.9% in the 3rd quarter. MetLife Investment Management LLC now owns 76,037 shares of the company’s stock worth $153,000 after acquiring an additional 34,243 shares during the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, February 27th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock opened at $1.93 on Friday. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The company’s fifty day moving average price is $1.65 and its 200-day moving average price is $1.91. The stock has a market cap of $395.65 million, a PE ratio of 3.06 and a beta of 0.91. Taysha Gene Therapies, Inc. has a 12 month low of $1.19 and a 12 month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The business had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $2.05 million. On average, equities analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.